Patients must be eligible for standard Lu-177-PSMA617 RLT for mCRPC, including PSMA PET/CT scan positive (lesion uptake \> liver uptake by visual assessment)
Patients must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (i.e., prior chemotherapy, external beam radiation, brachytherapy, immunotherapy, etc.)
Patients must be ≥18 years of age
Patients must have an ECOG performance status of 0 or 1
Bilirubin ≤ 1.5 x the institutional upper limit of normal (ULN). For patients with known Gilbert's Syndrome ≤ 3 x ULN is permitted
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 3.0 x ULN OR ≤ 5.0 x ULN for patients with liver metastases
Albumin \> 3.0 g/dL
Use effective birth control methods during the treatment and for 14 weeks after the last Lu-177-PSMA-617 dose
Ability to understand and the willingness to sign a written informed consent
You may not be if
Does not meet criteria for standard Lu-177-PSMA-617 RLT
Diffuse marrow involvement evident on Ga-68-PSMA PET/CT as assessed by study treating clinician
Prior RLT
Unmanageable concurrent bladder outflow obstruction or urinary incontinence
Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation
Plan to start any additional anti-cancer therapy or investigational agents during study therapy. Anti-cancer therapies include chemotherapy and endocrine therapy
